# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Roger Song initiates coverage on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy rating and announces Pri...
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price ta...
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to ...
-SEC Filing